Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

George V. Papatheodoridis; Ramazan Idilman; George N. Dalekos; Maria Buti; Heng Chi; Florian van Boemmel; Jose Luis Calleja; Vana Sypsa; Ioannis Goulis; Spilios Manolakopoulos; Federica Invernizzi; Spyros I. Siakavellas; Onur Keskin; Nikolaos Gatselis; Bettina E. Hansen; Maria Lehretz; Juan de la Revilla; Savvoula Savvidou; Anastasia Kourikou; Floriana Facchetti; Jiannis Vlachogiannakos; Kostas Galanis; Cihan Yurdaydin; Thomas Berg; Massimo Colombo; Rafael Esteban; Harry L. Janssen; Pietro Lampertico

Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

George V. Papatheodoridis
, Ramazan Idilman
, George N. Dalekos
, Maria Buti
, Heng Chi
, Florian van Boemmel
, Jose Luis Calleja
, Vana Sypsa
, Ioannis Goulis
, Spilios Manolakopoulos
, Federica Invernizzi
, Spyros I. Siakavellas
, Onur Keskin
, Nikolaos Gatselis
, Bettina E. Hansen
, Maria Lehretz
, Juan de la Revilla
, Savvoula Savvidou
, Anastasia Kourikou
, Floriana Facchetti

Jiannis Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L. Janssen, Pietro Lampertico

İç Hastalıkları Anabilim Dalı

Araştırma sonucu: Dergiye katkı › Toplantı Özeti › bilirkişi

Orijinal dil	İngilizce
Sayfa (başlangıç-bitiş)	1188A-1189A
Sayfa sayısı	2
Dergi	Hepatology
Hacim	62
Yayın durumu	Yayınlandı - Eki 2015

BM SKH

Bu sonuç, aşağıdaki Sürdürülebilir Kalkınma Hedefine/Hedeflerine katkıda bulunur

SKH 3 Sağlık ve Kaliteli Yaşam

Diger dosyalar ve linkler

View record in Web of Science

Bundan alıntı yap

Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Luis Calleja, J., Sypsa, V., Goulis, I., Manolakopoulos, S., Invernizzi, F., Siakavellas, S. I., Keskin, O., Gatselis, N., Hansen, B. E., Lehretz, M., de la Revilla, J., Savvidou, S., Kourikou, A., ... Lampertico, P. (2015). Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. Hepatology, 62, 1188A-1189A.

@article{bd1cdbd5cd774b468703142698215e00,

title = "Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients",

author = "Papatheodoridis, \{George V.\} and Ramazan Idilman and Dalekos, \{George N.\} and Maria Buti and Heng Chi and \{van Boemmel\}, Florian and \{Luis Calleja\}, Jose and Vana Sypsa and Ioannis Goulis and Spilios Manolakopoulos and Federica Invernizzi and Siakavellas, \{Spyros I.\} and Onur Keskin and Nikolaos Gatselis and Hansen, \{Bettina E.\} and Maria Lehretz and \{de la Revilla\}, Juan and Savvoula Savvidou and Anastasia Kourikou and Floriana Facchetti and Jiannis Vlachogiannakos and Kostas Galanis and Cihan Yurdaydin and Thomas Berg and Massimo Colombo and Rafael Esteban and Janssen, \{Harry L.\} and Pietro Lampertico",

year = "2015",

month = oct,

language = "English",

volume = "62",

pages = "1188A--1189A",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

}

Papatheodoridis, GV, Idilman, R, Dalekos, GN, Buti, M, Chi, H, van Boemmel, F, Luis Calleja, J, Sypsa, V, Goulis, I, Manolakopoulos, S, Invernizzi, F, Siakavellas, SI, Keskin, O, Gatselis, N, Hansen, BE, Lehretz, M, de la Revilla, J, Savvidou, S, Kourikou, A, Facchetti, F, Vlachogiannakos, J, Galanis, K, Yurdaydin, C, Berg, T, Colombo, M, Esteban, R, Janssen, HL & Lampertico, P 2015, 'Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients', Hepatology, hac. 62, pp. 1188A-1189A.

Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. / Papatheodoridis, George V.; Idilman, Ramazan; Dalekos, George N. et al.
In: Hepatology, Hac. 62, 10.2015, p. 1188A-1189A.

Araştırma sonucu: Dergiye katkı › Toplantı Özeti › bilirkişi

TY - JOUR

T1 - Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

AU - Papatheodoridis, George V.

AU - Idilman, Ramazan

AU - Dalekos, George N.

AU - Buti, Maria

AU - Chi, Heng

AU - van Boemmel, Florian

AU - Luis Calleja, Jose

AU - Sypsa, Vana

AU - Goulis, Ioannis

AU - Manolakopoulos, Spilios

AU - Invernizzi, Federica

AU - Siakavellas, Spyros I.

AU - Keskin, Onur

AU - Gatselis, Nikolaos

AU - Hansen, Bettina E.

AU - Lehretz, Maria

AU - de la Revilla, Juan

AU - Savvidou, Savvoula

AU - Kourikou, Anastasia

AU - Facchetti, Floriana

AU - Vlachogiannakos, Jiannis

AU - Galanis, Kostas

AU - Yurdaydin, Cihan

AU - Berg, Thomas

AU - Colombo, Massimo

AU - Esteban, Rafael

AU - Janssen, Harry L.

AU - Lampertico, Pietro

PY - 2015/10

Y1 - 2015/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000368375404256&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0270-9139

VL - 62

SP - 1188A-1189A

JO - Hepatology

JF - Hepatology

ER -